Researchers have conducted thousands of studies on metformin to treat various cancers, but no gold-standard trials support its efficacy against breast cancer or others.
Pamela Goodwin highlights a crucial point: despite metformin's popularity and economic advantages, there is no conclusive evidence that it effectively treats breast cancer.
Given its low cost and availability, many patients are eager to use metformin, but the considerable lack of definitive trial data leaves the medical community cautious.
Metformin may have intriguing laboratory results for slowing cancer cell growth, yet the absence of robust clinical trial support means it should not yet be a standard cancer treatment.
Collection
[
|
...
]